IDIPHISA’s Medical and Surgical Research Unit/Animal Facility (UIMQ/A)

The Medical-Surgical Research Unit/Animal Facility (UIMQ/A) of the Instituto de Investigación Puerta de Hierro-Segovia de Arana supports the Institute's various Research Services and Units, facilitating the development and housing of experimental animal models.

The UIMQ/A complies with European regulations (European Directive 2010/63/EU of the European Parliament and of the Council, of 22 September 2010, on the protection of animals used for scientific purposes) and national regulations (Royal Decree 53/2013, of 1 February, of the Ministry of the Presidency, establishing the basic rules applicable to the protection of animals used for experimentation and other scientific purposes, including teaching) regarding the use of laboratory animals.

The facilities were inspected by the Technical Section of the Animal Protection Area, under the Ministry of the Environment, Agriculture and the Interior, Directorate-General for Agriculture, Livestock and Food of the Community of Madrid. In a report issued on 5 March 2009, the Centre was authorised, under registration number ES280800000012, as a user and breeding establishment for rats and mice, and as a user of guinea pigs, rabbits, sheep and pigs, in accordance with the provisions of RD 53/2013. The authorisation was subsequently renewed on 19 December 2022.

The Institute has an Animal Experimentation Ethics Committee for the care and use of laboratory animals which, on 12 March 2014, was recognised as an Authorised Body for project assessment in accordance with RD 53/2013. 

Contact
animalario@idiphim.org
91 191 77 45

Location
C/ Joaquín Rodrigo, 2
Laboratory Building, ground floor
28222 Majadahonda, Madrid


The UIMQ/A, located on the ground floor of the research and laboratory building, has an area of approximately 700 m2². It is monitored by a CCTV circuit connected to the Hospital's Security Control Centre, and access to its facilities is restricted. It is divided into the following areas:

Animal facility:

  • A quarantine room with an animal reception area.
  • Two housing areas for rodents, guinea pigs and rabbits. These consist of a distribution and work room and various housing rooms:
    • – Two for rats
    • – Two for mice
    • – One for rabbits and guinea pigs

All housing rooms have light cycle, temperature and humidity control. They are also fitted with individually ventilated racks, U-TEMP polyetherimide microisolators of various sizes and species (rats, mice and guinea pigs), and a transfer cabinet for handling SPF and immunosuppressed animals.

  • Two housing rooms for large animals.
  • A cleaning and disinfection room equipped with two cage washers.
  • Three storage rooms for materials, feed, bedding and equipment.

Laboratories and experimental operating theatres:

  • An experimental work room for rodents equipped with two surgical microscopes.
  • Two experimental operating theatres with independent acclimatisation and positive pressure, equipped with anaesthesia stations and vital sign monitoring equipment.
  • A multifunctional laboratory.

The UIMQ/A's total animal capacity allows for the housing of 700 rats, 900 mice, 40 guinea pigs, 6 rabbits and 6 pigs/sheep.

Staff

Staff assigned to the UIMQ/A are trained in the functions required to handle and care for laboratory animals in accordance with Order ECC/566/2015, of 20 March, which establishes the training requirements for staff handling animals used, bred or supplied for experimentation and other scientific purposes, including teaching.

  • Designated veterinarian responsible «in situ» for animal welfare.
    • – Martín Santos González
  • Part-time animal caretaker.

Research

  1. Guidance and support for research with laboratory animals.
  2. Development of laboratory animal models for research.
  3. Development of in-house and third-party projects.
  4. Support for processing the results of projects carried out with laboratory animals.

Training

  1. Development of laboratory animal models for medical-surgical teaching.
  2. Organisation and delivery of courses using simulators, anatomical specimens and laboratory animals.
  3. Support for the Simulation Unit.
  4. Support for staff Continuing Education.
  5. Continuing Education to maintain qualification in laboratory animal handling functions.

Management

  1. Health and welfare management of animals housed in the animal facility.
  2. Participation in Committees (Animal Experimentation Ethics Committee, Authorised Body, Biological Safety Committee).
  3. Management of projects carried out with laboratory animals.
  4. Management of the Experimental Models Research Group.
  5. Liaison with other experimental Centres.
  6. Liaison, for reporting statistical and application data, with the Community of Madrid's Animal Protection Area (Hamellin Programme) and with the European Union (Alures Programme).

Recognition of qualification to handle laboratory animals

Researchers who hold courses for handling laboratory animals, have completed supervised practical training and wish to request recognition of their qualification for functions a, b and/or c can do so by downloading the following document:

Once completed, it will be processed at the Community of Madrid's Animal Protection Area by sending the course certificate and the document certifying that the supervised practical training was completed, following the instructions found in the document Qualification Recognition Instructions.

If the qualification you wish to request is for function d, supervised practical training will not be necessary. Processing at the Community of Madrid's Animal Protection Area will involve sending the course certificate and a copy of the degree certificate, following the instructions found in the document Qualification Recognition Instructions.

Maintenance of qualification to handle laboratory animals

Researchers whose qualification recognition expires for any of the functions can carry out the qualification maintenance process at the Community of Madrid's Animal Protection Area by sending the course certificates proving the hours required to maintain qualification in those functions, following the instructions found in the document Qualification Maintenance Instructions.

Animal experimentation authorisation

Researchers who require a report from the CEEA and/or Authorised Body must download the following documents:

Once completed, they must be sent by e-mail to the CEEA secretary, requesting assessment of the research and/or teaching project, indicating this in the e-mail subject line.

Once the project has been assessed, the reports will be sent to the applicant for processing at the Community of Madrid's Animal Protection Area, following the instructions found in the document Animal Experimentation Authorisation Instructions.

ONGOING PROJECTS
  • 2025-actualidad: Papel de la microbiota intestinal en la respuesta a la quimio-inmunoterapia en cáncer de pulmón de células no pequeñas. PI24/01725 (ISCIII). Amount: 340.000 €. IP: Atocha Romero.
  • 2022-actualidad: Validación clínica de un sistema para detectar translocaciones de ALK en vesículas extracelulares en plasma III. DTS21/00124 (ISCIII). Amount: 88.550,00€ (budget exclusive to the PI's institution). PI. Coordinator (multicentre study): Atocha Romero.
  • 2022-present: Biomarkers4Cure. Biomarcadores predictivos de respuesta a combinaciones de inmunoterapia más quimioterapia neoadyuvante en pacientes con cáncer de pulmón operable. PI21/01500 (ISCIII). Amount: €266.00. IP: Atocha Romero.
  • 2020-actualidad: Investigador colaborador en el proyecto RETOS-COLABORACIÓN titulado “BLI-O. Desarrollo de marcadores moleculares en biopsia liquida para larga supervivencia en oncoinmunoterapia (I-O)”. RTC2019- 007359-1. PI: Mariano Provencio.
  • 2022–present: Determinación de mutaciones DDR en una cohorte de pacientes con CPRCm mediante biopsia líquida (ctDNA). Concordancia con el estudio germinal y en tejido tumoral. PI 175/21. PI: Atocha Romero
  • 2023-2025: Quimio-inmunoterapia en estadios localmente avanzados deCPCNP: validación de marcadores derivados del ctDNA y el microambiente tumoral. Funding body and call: ISCIII (AES 2022). PI22/01223. Cuantía: 268.620 €. PI: Mariano Provencio (HUPH).
SELECTED PUBLICATIONS
  1. Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28. PMID: 37379158.
  2. Provencio M, et al. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial. 2022. JAMA Oncol. Online ahead of print. doi: 10.1001/jamaoncol.2022.5959.
  3. Provencio M et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J Clin Oncol, 40(25):2924 2933. doi: 10.1200/JCO.21.02660
  4. Sánchez-Herrero E, et al. ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing. Clin Chem. 2022 Mar 28;hvac021.
  5. Casarrubios M,et al. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. 2021. Clin Cancer Res, 27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200.
  6. Sierra-Rodero B, Cruz-Bermúdez A (CA), Nadal E, … Provencio M (CA) (26/26). Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J Immunother Cancer, 9(8): e002804. doi: 10.1136/jitc-2021-002804.
  7. Sánchez-Herrero E, et al. NGS-based liquid-biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step towards personalized NSCLC treatment. Mol Oncol. 2021 May 31. doi: 10.1002/1878-0261.13033
  8. Laza-Briviesca R, et al. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant Chemoimmunotherapy included in NADIM clinical trial. 2021. Clin Transl Med, 11(7):e491. doi: 10.1002/ctm2.491.
  9. Pérez-Barrios C, et al. ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma. Clin Chem Lab Med. Clin Chem Lab Med. 2021 Mar 11;59(7):1221-1229
  10. Provencio M et al. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. Eur J Cancer, 149:61-72. doi: 10.1016/j.ejca.2021.02.031.
  11. Provencio M et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open label, multicentre, single-arm, phase 2 trial. 2020. Lancet Oncol, 21(11):1413 1422. doi: 1016/S1470-2045(20)30453-8.

↑